Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast...
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...